Ornithine Injection

Generic Name: L-Ornithine (commonly available clinically as L-Ornithine-L-Aspartate [LOLA])
Drug Class: Non-proteinogenic amino acid; urea-cycle intermediate; ammonia-detoxification agent.
Route of Administration: Intravenous (IV).
Pharmaceutical Form:

• Injectable solutions of L-Ornithine L-Aspartate (large-volume infusion 5–20 g).
• Ornithine as a pure amino acid is rarely formulated alone for IV use; instead, LOLA is the standard.

Therapeutic Uses:

• Treatment of hyperammonemia
• Hepatic encephalopathy (acute or chronic)
• Support of ammonia detoxification pathways in liver dysfunction
• Adjunct therapy in severe hepatic insufficiency
• Experimental use in wound healing and metabolic support (non-standard)

Ornithine is NOT included in standard PN amino-acid mixtures.

A. Standard Adult Dosing (for IV Ornithine-L-Aspartate)

• 20–40 grams/day IV infusion, typically in 500–1000 mL
• Administered over 4–24 hours, depending on clinical severity
• Used for hyperammonemia or hepatic encephalopathy grades I–III

B. Higher-Severity Cases

• Severe encephalopathy may require up to 30–40 g/day continuous infusion, monitored in ICU.

C. Administration Guidelines

• Infuse via peripheral or central line depending on osmolarity
• Do not administer as IV push
• Monitor neurological status and serum ammonia levels
• Use continuous infusion to avoid fluctuations

D. Adjustments in Special Populations

• Renal impairment: Use caution; metabolites (urea/ornithine cycle intermediates) may accumulate.

Severe hepatic failure: Dose may be increased for ammonia clearance but requires strict monitoring.

L-Ornithine plays key roles in ammonia detoxification and metabolic homeostasis:

A. Urea Cycle Substrate (Primary Mechanism)

Ornithine is required for the entry of ammonia into the urea cycle:

1. Ornithine + Carbamoyl phosphate → Citrulline
2. Citrulline → Argininosuccinate → Arginine → Urea + Ornithine (regenerated)

This mechanism:

• Reduces blood ammonia
• Supports detoxification in liver dysfunction
• Prevents neurotoxicity from hyperammonemia

B. Glutamine Synthesis Pathway Support

Ornithine stimulates conversion of ammonia to glutamine in peripheral tissues:

• Especially in skeletal muscle
• Reduces circulating ammonia load delivered to the brain

C. Mitochondrial Function and Energy Metabolism

Ornithine supports:

• TCA cycle intermediates
• Improved hepatic mitochondrial function
• Enhanced ammonia clearance at hepatocyte level

D. Collagen Synthesis (Indirect)

Through the conversion of ornithine → proline, there is a role in:

• Wound healing
• Tissue repair
• Fibroblast activity

E. Growth Hormone Stimulation (Theoretical / Limited Evidence)

High oral doses increase GH secretion; relevance for IV forms is minimal clinically.

Absolute Contraindications

1. Severe renal insufficiency
   1. Risk of accumulation of metabolites (urea, glutamine)
2. Known hypersensitivity to ornithine, aspartate, or formulation components
3. Metabolic disorders of the urea cycle
   1. OTC deficiency
   2. CPS1 deficiency
      (Ornithine will not correct underlying defects and may worsen metabolic instability)

Relative Contraindications

• Severe dehydration or hypovolemia – risk of worsened hyperammonemia
• Respiratory alkalosis – urea cycle substrate changes
• Advanced hepatic coma grade IV – limited efficacy at critical stage
• Electrolyte abnormalities (especially hypokalemia or alkalosis)

Monitoring Requirements

• Serum ammonia
• Liver function tests
• Mental status / encephalopathy staging
• Serum electrolytes
• Renal function
• Acid–base balance

Blood urea nitrogen (BUN)

Drug Interactions

• Lactulose – synergistic ammonia-lowering effect (beneficial, not harmful)
• Rifaximin / Neomycin – used together for encephalopathy; no negative interaction
• Corticosteroids – may impair ammonia detoxification, requiring dose adjustments
• Valproic acid – worsens hyperammonemia; ornithine may partially counteract
• Protein loads (TPN) – may increase ammonia; require increased monitoring when ornithine is used

Nutritional / Metabolic Interactions

• Low carbohydrate intake increases endogenous ammonia → may increase ornithine requirements
• Zinc deficiency may impair urea cycle enzyme function (especially OTC)

Common

• Nausea
• Vomiting
• Abdominal discomfort
• Mild hypotension during infusion
• Sweating or warmth sensation
• Local infusion site irritation

Metabolic Effects

• Reduced ammonia levels (therapeutic)
• Possible mild alkalosis due to increased urea cycle activity
• Increased BUN as urea excretion rises
• Rare occurrences of:
  • Hypernatremia
  • Hyperchloremia

Rare / Severe

• Allergic reaction
• Confusion or worsening encephalopathy (if underlying pathology worsens)
• Renal overload with high-dose use
• Pulmonary edema in volume-sensitive patients (heart failure, cirrhosis with ascites)

PREGNANCY & BREASTFEEDING

Pregnancy

• No evidence of teratogenicity at therapeutic doses
• Should only be used if benefits outweigh risks (e.g., severe hyperammonemia)
• Monitor ammonia levels very closely
• Avoid high-dose prolonged therapy without metabolic consultation

Breastfeeding

• No known harmful excretion into breast milk at standard doses
• Generally considered safe when required for maternal treatment

Monitor maternal liver function and ammonia clearance

For IV Ornithine / Ornithine-Aspartate Solutions:

• Temperature: 20–25°C (68–77°F)
• Do not freeze
• Protect from excessive heat
• Store in original packaging
• Inspect visually for:
  • Cloudiness
  • Precipitation
  • Discoloration
  • Container integrity
• Use aseptic technique during preparation
• Follow institutional policies for beyond-use dating once opened

(Professional medical and pharmacological sources—no URLs)

1. European Association for the Study of the Liver (EASL): Guidelines on the Management of Hepatic Encephalopathy.
2. ASPEN: Clinical Guidelines for Parenteral Nutrition.
3. Fischer CP, Baldus WP. Pharmacology of L-Ornithine-L-Aspartate in Hyperammonemia.
4. Textbook of Hepatology – Ammonia Metabolism & Urea Cycle.
5. S. Pharmacopeia (USP) – Amino Acid Injection Standards.
6. Basic Medical Biochemistry – Urea Cycle and Amino Acid Metabolism.
7. Pharmacology Resources on LOLA for Hepatic Encephalopathy (peer-reviewed literature).